BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] HIV-related large B-cell lymphoma confined to the bone marrow with a fulminant clinical course: a case report and literature review.

[MeSH-major] Bone Marrow / pathology. Lymphoma, AIDS-Related / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

Genetic Alliance. consumer health - HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17982403.001).

[ISSN] 1543-0790

[Journal-full-title] Clinical advances in hematology & oncology : H&O

[ISO-abbreviation] Clin Adv Hematol Oncol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy.

In the era of highly active antiretroviral treatment (HAART), the prognosis of AIDS-related lymphomas might be similar to that of aggressive B-cell lymphomas in human immunodeficiency (HIV)-negative patients.

In this study we found that HIV-infected patients with diffuse large B-cell lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone (CHOP) and HAART showed a similar response rate to chemotherapy, disease-free survival and overall survival as those of HIV-negative patients receiving CHOP.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / mortality. Lymphoma, AIDS-Related / mortality. Lymphoma, Large B-Cell, Diffuse / mortality

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15921395.001).

[ISSN] 1592-8721

[Journal-full-title] Haematologica

[ISO-abbreviation] Haematologica

[Language] eng

[Publication-type] Letter; Research Support, Non-U.S. Gov't

[Publication-country] Italy

[Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Cutaneous presentation of plasmablastic lymphoma in a patient with HIV Infection].

[MeSH-major] Lymphoma, AIDS-Related / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Skin Neoplasms / diagnosis

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - Skin Cancer.

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19091226.001).

[ISSN] 0001-7310

[Journal-full-title] Actas dermo-sifiliográficas

[ISO-abbreviation] Actas Dermosifiliogr

[Language] spa

[Publication-type] Case Reports; Letter

[Publication-country] Spain

[Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol

   

Advertisement

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The rarity of primary effusion lymphomas and plasmablastic lymphomas of the oral cavity type makes large prospective studies difficult and challenges the feasibility of defining therapy specific for a given subpopulation of patients.

However, rituximab plus chemotherapy should be offered to the majority of patients with HIV infection and diffuse large B-cell lymphomas; and the feasibility of intensive aggressive chemotherapy regimens has been successfully tested in HIV-associated Burkitt's lymphomas.

[MeSH-major] HIV Infections / complications. HIV Infections / drug therapy. Lymphoma, AIDS-Related / complications. Lymphoma, AIDS-Related / drug therapy

[MeSH-minor] Animals. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active / trends. Boronic Acids / therapeutic use. Bortezomib. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / drug therapy. Humans. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / drug therapy. Pyrazines / therapeutic use. Rituximab. Treatment Outcome

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

Hazardous Substances Data Bank. RITUXIMAB .

Hazardous Substances Data Bank. BORTEZOMIB .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20726820.001).

[ISSN] 1744-7666

[Journal-full-title] Expert opinion on pharmacotherapy

[ISO-abbreviation] Expert Opin Pharmacother

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Boronic Acids; 0 / Pyrazines; 0 / ofatumumab; 4F4X42SYQ6 / Rituximab; 69G8BD63PP / Bortezomib

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Diffuse large B-cell lymphoma on the back of a patient with AIDS: successful treatment by the CD20 monoclonal antibody rituximab.

[MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / drug therapy

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

Hazardous Substances Data Bank. RITUXIMAB .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16336543.001).

[ISSN] 0011-9059

[Journal-full-title] International journal of dermatology

[ISO-abbreviation] Int. J. Dermatol.

[Language] eng

[Publication-type] Case Reports; Letter

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] StatBite: Lymphoma incidence in HIV patients vs. general population.

[MeSH-major] Lymphoma, AIDS-Related / epidemiology. Lymphoma, AIDS-Related / virology

[MeSH-minor] Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / virology. Central Nervous System Neoplasms / epidemiology. Central Nervous System Neoplasms / virology. HIV Infections / complications. Hodgkin Disease / epidemiology. Hodgkin Disease / virology. Humans. Incidence. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Large B-Cell, Diffuse / virology. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / virology

Genetic Alliance. consumer health - HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20616355.001).

[ISSN] 1460-2105

[Journal-full-title] Journal of the National Cancer Institute

[ISO-abbreviation] J. Natl. Cancer Inst.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Patients with HIV with Burkitt's lymphoma have a worse outcome than those with diffuse large-cell lymphoma also in the highly active antiretroviral therapy era.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Burkitt Lymphoma / mortality. Lymphoma, AIDS-Related / mortality. Lymphoma, Large B-Cell, Diffuse / mortality

Genetic Alliance. consumer health - Lymphoma, large-cell.

Genetic Alliance. consumer health - HIV.

Genetic Alliance. consumer health - Burkitt's Lymphoma.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentOn] J Clin Oncol. 2005 Jul 1;23(19):4430-8 [15883411.001]

(PMID = 16258119.001).

[ISSN] 0732-183X

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Comment; Comparative Study; Letter

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Primary mediastinal large B-cell lymphoma in an HIV-infected patient.

HIV-related non-Hodgkin lymphoma is well documented in the literature.

We report a case of an HIV-infected patient who presents with primary mediastinal large B-cell lymphoma.

On review of the literature, this appears to be the first documented case of this subtype of large B-cell non-Hodgkin lymphoma seen in an HIV-infected patient.

[MeSH-major] Lymphoma, AIDS-Related / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Mediastinal Neoplasms / diagnosis

Genetic Alliance. consumer health - HIV.

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15767818.001).

[ISSN] 0002-9629

[Journal-full-title] The American journal of the medical sciences

[ISO-abbreviation] Am. J. Med. Sci.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma.

Kaposi sarcoma-associated herpesvirus (KSHV) is known to be associated with two distinct lymphoproliferative disorders: primary effusion lymphoma (PEL) and multicentric Castleman disease (MCD)/MCD-associated plasmablastic lymphoma.

Within a cohort of 99 HIV-related NHLs, 10 cases were found to be KSHV positive on the basis of immunostaining for KSHV LNA-1 as well as KSHV-specific polymerase chain reaction.

Interestingly, all KSHV-positive cases belonged to a distinctive subgroup of 26 diffuse large B-cell lymphomas characterized by the expression of CD138 (syndecan-1) and plasmablastic/immunoblastic morphology.

Our results indicate that KSHV infection is not restricted to PEL and MCD; it is also common (38%) in HIV-related solid immunoblastic/plasmablastic lymphomas.

[MeSH-major] Giant Lymph Node Hyperplasia / virology. HIV Infections / virology. Herpesviridae Infections / virology. Herpesvirus 8, Human. Lymphoma, AIDS-Related / virology. Lymphoma, Large B-Cell, Diffuse / virology. Sarcoma, Kaposi / virology

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15744337.001).

[ISSN] 0887-6924

[Journal-full-title] Leukemia

[ISO-abbreviation] Leukemia

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: It is diagnostically difficult to differentiate plasmablastic lymphomas (PBLs) from plasma cell neoplasms with plasmablastic differentiation.

Positivity was recorded based on the percentage of positive staining cells as focal (5-20%); intermediate (20-70%) or diffuse (>70%).

Diffuse and strong positive staining was found with Ki-67 and MUM1, but variable immunoreactivity was found with CD79a, CD45, CD38 and CD138.

[MeSH-major] Lymphoma, AIDS-Related / classification. Lymphoma, Large-Cell, Immunoblastic / classification. Mouth Mucosa / pathology. Mouth Neoplasms / classification. Plasmacytoma / classification

[MeSH-minor] Adult. Cell Differentiation. Female. HIV Seropositivity / complications. Herpesvirus 4, Human / isolation & purification. Humans. Immunoglobulin Light Chains / analysis. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. RNA, Viral / analysis. Retrospective Studies. South Africa

MedlinePlus Health Information. consumer health - Oral Cancer.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20537055.001).

[ISSN] 1600-0714

[Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology

[ISO-abbreviation] J. Oral Pathol. Med.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Denmark

[Chemical-registry-number] 0 / Epstein-Barr virus encoded RNA 1; 0 / Epstein-Barr virus encoded RNA 2; 0 / Immunoglobulin Light Chains; 0 / RNA, Viral

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles.

Plasmablastic lymphoma is an aggressive neoplasm that shares many cytomorphologic and immunophenotypic features with plasmablastic plasma cell myeloma.

However, plasmablastic lymphoma is listed in the World Health Organization (WHO) classification as a variant of diffuse large B-cell lymphoma.

To characterize the relationship between plasmablastic lymphoma and plasmablastic plasma cell myeloma, we performed immunohistochemistry using a large panel of B-cell and plasma cell markers on nine cases of plasmablastic lymphoma and seven cases of plasmablastic plasma cell myeloma with and without HIV/AIDS.

All cases of plasmablastic lymphoma and plasmablastic plasma cell myeloma were positive for MUM1/IRF4, CD138, and CD38, and negative for CD20, corresponding to a plasma cell immunophenotype.

PAX-5 and BCL-6 were weakly positive in 2/9 and 1/5 plasmablastic lymphomas, and negative in all plasmablastic plasma cell myelomas.

Three markers that are often aberrantly expressed in cases of plasma cell myelomas, CD56, CD4 and CD10, were positive in 5/9, 2/5, and 6/9 plasmablastic lymphomas, and in 3/7, 1/5, and 2/7 plasmablastic plasma cell myelomas.

The only significant difference between plasmablastic lymphoma and plasma cell myeloma was the presence of EBV-encoded RNA, which was positive in all plasmablastic lymphoma cases tested and negative in all plasma cell myelomas.

In conclusion, most cases of AIDS-related plasmablastic lymphoma have an immunophenotype and tumor suppressor gene expression profile virtually identical to plasmablastic plasma cell myeloma, and unlike diffuse large B-cell lymphoma.

These results do not support the suggestion in the WHO classification that plasmablastic lymphoma is a variant of diffuse large B-cell lymphoma.

[MeSH-major] Immunophenotyping. Lymphoma / pathology. Multiple Myeloma / pathology. Plasma Cells / pathology

[MeSH-minor] Adult. Aged. Antigens, CD / analysis. DNA, Viral / genetics. DNA-Binding Proteins / analysis. Epstein-Barr Virus Infections / immunology. Epstein-Barr Virus Infections / pathology. Epstein-Barr Virus Infections / virology. Female. Herpesvirus 4, Human / genetics. Herpesvirus 8, Human / genetics. Humans. Immunohistochemistry. In Situ Hybridization. Ki-67 Antigen / analysis. Lymphoma, AIDS-Related / immunology. Lymphoma, AIDS-Related / pathology. Lymphoma, AIDS-Related / virology. Male. Middle Aged. Polymerase Chain Reaction. Proto-Oncogene Proteins / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Proto-Oncogene Proteins c-bcl-6. Transcription Factors / analysis. Tumor Suppressor Protein p53 / analysis

MedlinePlus Health Information. consumer health - Lymphoma.

MedlinePlus Health Information. consumer health - Multiple Myeloma.

COS Scholar Universe. author profiles.

HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[ErratumIn] Mod Pathol. 2005 Jun;18(6):873. Medeiros, Leonard J [corrected to Medeiros, L Jeffrey]

(PMID = 15578069.001).

[ISSN] 0893-3952

[Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

[ISO-abbreviation] Mod. Pathol.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD; 0 / DNA, Viral; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Raltegravir-based HAART regimen in a patient with large B-cell lymphoma.

OBJECTIVE: To describe the antiretroviral management of a patient diagnosed simultaneously with HIV/AIDS and diffuse large B-cell lymphoma, focusing on the drug-drug interactions between highly active antiretroviral therapy (HAART) and concomitant cancer chemotherapy.

CASE SUMMARY: A 55-year-old white man was recently diagnosed with HIV/AIDS and presented 1 month later with complaints of nausea, vomiting, abdominal pain, double vision, right eye discomfort/swelling, and a 3.6-kg weight loss.

An excisional biopsy of a right inguinal lymph node confirmed a new diagnosis of diffuse large B-cell lymphoma.

DISCUSSION: HAART improves the chemotherapeutic response in patients with HIV and lymphoma.

[MeSH-minor] Antiretroviral Therapy, Highly Active / methods. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Drug Interactions. HIV Integrase Inhibitors / therapeutic use. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / etiology. Male. Methotrexate / administration & dosage. Middle Aged. Prednisone / therapeutic use. Raltegravir Potassium. Vincristine / therapeutic use

MedlinePlus Health Information. consumer health - HIV/AIDS.

HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. Raltegravir .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

Hazardous Substances Data Bank. METHOTREXATE .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20040700.001).

[ISSN] 1542-6270

[Journal-full-title] The Annals of pharmacotherapy

[ISO-abbreviation] Ann Pharmacother

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / HIV Integrase Inhibitors; 0 / Pyrrolidinones; 43Y000U234 / Raltegravir Potassium; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Behaviour of HIV/AIDS-related lymphoma in Pedro Kouri Institute. 2004-2005].

A prospective and descriptive study of 20 patients infected with HIV and admitted to "Pedro Kouri" Institute of Tropical Disease after a diagnosis of lymphoma was conducted.

Of this number, 85% presented with CD4+ count under 350 cell/mm3 at the time of diagnosis; however, only 55% showed viral loads exceeding 50,000 copies/mL.

The predominant histological subtype was large diffuse cells and the most frequent location was the extrapulmonary site in 70% of cases.

It called our attention that high levels of lactic acid dehydrogenase and extrapulmonary location of tumors were related.

Statistically significant association was found (p < 0.05) between immunosuppresion condition of the patients given by CD4+ count below 350 cell/mm3 and advanced staging of the tumoral disease (stages III and IV).

[MeSH-major] Lymphoma, AIDS-Related / epidemiology

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 23424794.001).

[ISSN] 0375-0760

[Journal-full-title] Revista cubana de medicina tropical

[ISO-abbreviation] Rev Cubana Med Trop

[Language] spa

[Publication-type] English Abstract; Journal Article

[Publication-country] Cuba

[Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.1.27 / L-Lactate Dehydrogenase

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS and non AIDS-related malignant lymphoma in Tanzania.

BACKGROUND: Malignant lymphoma (ML) in HIV patients, are second in frequency to Kaposi's sarcoma (AKS) as AIDS-defining tumors.

In Africa the frequency of AIDS-related lymphoma (ARL) is rare and the findings are controversial.

Both retrospective and prospective lymphoma cases were classified according to the revised European-American (REAL) classification.

OBJECTIVES: To determine the frequency and type of AIDS and non-AIDS related malignant lymphoma in Tanzania and a possible co-association with KSHV/HHV-8 and EBV.

The tumors were classified as Burkitt's (6), diffuse large cell (10), precursor-B lymphoblastic (1) and Hodgkin's disease (5) from HIV positive and negative patients.

Ten (40%) high grade ML and three Hodgkin's lymphoma from HIV patients had HHV-8 DNA.

These findings were not related to age, sex or type of lymphoma.

There was no association of HHV-8 with the lymphoma cells.

CONCLUSIONS: This study suggests an overall increased frequency of ML patients infected with HHV-8 in Tanzania particularly in HIV patients which may result from the well established high HHV-8 prevalence in the general population, but HHV-8 was not associated with ARL pathogenesis as reflected by lack of tumor cell infection.

[MeSH-major] Lymphoma / epidemiology. Lymphoma / pathology. Lymphoma, AIDS-Related / epidemiology

[MeSH-minor] Adolescent. Adult. Aged. Biopsy, Needle. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / pathology. Child. Child, Preschool. Developing Countries. Female. Herpesvirus 4, Human / isolation & purification. Herpesvirus 8, Human / isolation & purification. Hodgkin Disease / epidemiology. Hodgkin Disease / pathology. Humans. Immunohistochemistry. In Situ Hybridization. Incidence. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Polymerase Chain Reaction. Registries. Retrospective Studies. Risk Assessment. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / pathology. Sarcoma, Kaposi / virology. Survival Analysis. Tanzania / epidemiology. Young Adult

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - Lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Natl Cancer Inst Monogr. 1998;(23):79-88 [9709308.001]

[Cites] Br J Cancer. 1997;75(11):1704-7 [9184191.001]

[Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264 [16020424.001]

[Cites] Curr HIV/AIDS Rep. 2004 Apr;1(1):5-11 [16091217.001]

[Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]

[Cites] Scand J Infect Dis. 1994;26(6):749-52 [7747100.001]

[Cites] Int J Cancer. 1995 May 16;61(4):574-9 [7759163.001]

[Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]

[Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]

[Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]

[Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Nov 1;10(3):295-305 [7552491.001]

[Cites] AIDS. 2002 Mar 8;16(4):597-603 [11873003.001]

[Cites] J Med Virol. 2002 Oct;68(2):264-7 [12210417.001]

[Cites] Lancet Oncol. 2003 Feb;4(2):110-9 [12573353.001]

[Cites] Rev Clin Exp Hematol. 2003 Dec;7(4):375-405 [15129649.001]

[Cites] MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373-5 [2989677.001]

[Cites] N Engl J Med. 1985 Dec 19;313(25):1564-71 [2999595.001]

[Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]

[Cites] J Histochem Cytochem. 1991 Jun;39(6):741-8 [1709656.001]

[Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]

[Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]

[Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]

[Cites] Science. 1995 Apr 28;268(5210):582-3 [7725108.001]

[Cites] Nat Med. 1995 Jul;1(7):707-8 [7585156.001]

[Cites] Nat Med. 1995 Dec;1(12):1274-8 [7489408.001]

[Cites] J Virol. 1996 Jan;70(1):549-58 [8523568.001]

[Cites] N Engl J Med. 1996 Jan 25;334(4):272-3 [8532016.001]

[Cites] Arch Intern Med. 1996 Jan 22;156(2):202-4 [8546554.001]

[Cites] Br J Haematol. 1995 Dec;91(4):918-20 [8547139.001]

[Cites] Am J Clin Pathol. 1996 Feb;105(2):221-9 [8607449.001]

[Cites] Blood. 1996 May 1;87(9):3903-9 [8611719.001]

[Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]

[Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]

[Cites] J Mol Med (Berl). 1995 Dec;73(12):603-9 [8825757.001]

[Cites] AIDS. 1996 Aug;10(9):951-8 [8853727.001]

[Cites] J Virol. 1997 Mar;71(3):2505-11 [9032391.001]

[Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]

(PMID = 16916294.001).

[ISSN] 1729-0503

[Journal-full-title] African health sciences

[ISO-abbreviation] Afr Health Sci

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Uganda

[Other-IDs] NLM/ PMC1831982

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Update in HIV lymphoma.

Lymphoma is the most common HIV-associated malignancy in these countries.

RECENT FINDINGS: Investigators continue to demonstrate that HIV-associated non-Hodgkin's lymphoma remains a significant problem, even in the era of highly active antiretroviral therapy.

The majority of work has been in diffuse large B-cell lymphoma, with infusional therapy remaining promising, and rituximab an area of investigation.

Biological insights have been gained into the spectrum of HIV-associated non-Hodgkin's lymphoma and Hodgkin's disease, and include further work on virological co-infections.

SUMMARY: The outcome for individuals infected with HIV and developing non-Hodgkin's lymphoma and Hodgkin's disease continues to improve as insights into the pathophysiology and treatment advance.

[MeSH-major] Anti-Retroviral Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy

Genetic Alliance. consumer health - HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16894292.001).

[ISSN] 1040-8746

[Journal-full-title] Current opinion in oncology

[ISO-abbreviation] Curr Opin Oncol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Anti-Retroviral Agents

[Number-of-references] 45

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Primary lymphoma of the central nervous system: a clinical-pathological and immunohistochemical study of ten autopsy cases.

METHOD: The clinical, histological and immunohistochemical data of ten cases of PCNSL, eight cases from patients with AIDS, identified among 265 autopsies of these patients were analyzed.

Most patients had diffuse large B cell non-Hodgkins lymphoma.

CONCLUSION: In the present series, PCNSL presented with focal symptoms, with unifocal or multifocal lesions, with a predominant B-cell CD20 positive phenotype, rarely associated with EBV.

[MeSH-major] Central Nervous System Neoplasms / pathology. Lymphoma / pathology

[MeSH-minor] Adult. Autopsy. Epstein-Barr Virus Infections / pathology. Epstein-Barr Virus Infections / virology. Female. Humans. Immunohistochemistry. Lymphoma, AIDS-Related / pathology. Lymphoma, AIDS-Related / virology. Male. Middle Aged

Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.

Genetic Alliance. consumer health - TEN.

MedlinePlus Health Information. consumer health - Lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17221007.001).

[ISSN] 0004-282X

[Journal-full-title] Arquivos de neuro-psiquiatria

[ISO-abbreviation] Arq Neuropsiquiatr

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Brazil

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.

Non-Hodgkin's lymphoma (NHL) remains an important complication of associated HIV infection despite advances in antiretroviral therapy (ART), and the optimum chemotherapy regimen for this disease remains to be defined.

Patients with aggressive histology HIV-related NHL who were previously untreated with chemotherapy, and who had no active opportunistic infection were eligible for the study.

Forty-seven patients were enrolled, most with diffuse large-cell or immunoblastic NHL.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy

Genetic Alliance. consumer health - HIV.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. BLEOMYCIN .

Hazardous Substances Data Bank. Filgrastim .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. ETOPOSIDE .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16216784.001).

[ISSN] 1387-2656

[Journal-full-title] Biotechnology annual review

[ISO-abbreviation] Biotechnol Annu Rev

[Language] eng

[Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Recombinant Proteins; 11056-06-7 / Bleomycin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; PVI5M0M1GW / Filgrastim; VB0R961HZT / Prednisone; VACOP-B protocol

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.

Immunochemotherapy with cyclophosphamide, adriamycin, vincristine, prednisone and rituximab (R-CHOP) is the standard treatment in non-immunosuppressed patients with diffuse large B-cell lymphoma (DLBCL), but its adequacy has not been definitively established in patients with human immunodeficiency virus (HIV)-related lymphoma.

This phase II trial aimed to evaluate the safety and efficacy of six cycles of R-CHOP in patients with HIV-related DLBCL and to determine whether response to highly active antiretroviral therapy (HAART) had prognostic impact.

In HIV-related DLBCL R-CHOP is feasible, safe and effective.

The prognosis depends on lymphoma-related parameters and on the response to HAART.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

Hazardous Substances Data Bank. RITUXIMAB .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18162120.001).

[ISSN] 1365-2141

[Journal-full-title] British journal of haematology

[ISO-abbreviation] Br. J. Haematol.

[Language] eng

[Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prolonged survival of an HIV-infected patient with plasmablastic lymphoma of the oral cavity.

Plasmablastic lymphoma is an aggressive subtype of diffuse large B-cell lymphoma that is mainly observed in patients with the human immunodeficiency virus (HIV) infection, and it tends to arise in the oral cavity.

We present a case of an HIV-infected patient with plasmablastic lymphoma with prolonged survival.

Histological and immunochemical examination of biopsy of the oral lesion showed plasmablastic lymphoma (CD138+).

The patient remains in complete remission 61 months after the diagnosis of plasmablastic lymphoma.

[MeSH-major] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / pathology. Lymphoma, AIDS-Related / etiology. Lymphoma, AIDS-Related / pathology. Mouth / pathology

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

COS Scholar Universe. author profiles.

HIV InSite. treatment guidelines - Women and HIV .

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17094093.001).

[ISSN] 0361-8609

[Journal-full-title] American journal of hematology

[ISO-abbreviation] Am. J. Hematol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma.

BACKGROUND: Plasmablastic lymphoma (PBL) is a variant of diffuse large B-cell lymphoma commonly seen in the oral cavity of HIV-infected individuals.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. HIV Infections / complications. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large-Cell, Immunoblastic / drug therapy. Lymphoma, Large-Cell, Immunoblastic / virology

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Clin Oncol (R Coll Radiol). 2000;12(3):194 [10942339.001]

[Cites] J Hematol Oncol. 2009;2:47 [19909553.001]

[Cites] Leuk Lymphoma. 2002 Feb;43(2):423-6 [11999580.001]

[Cites] Br J Haematol. 2002 Dec;119(3):622-8 [12437635.001]

[Cites] AIDS. 2003 Jul 4;17(10):1582-4 [12824797.001]

[Cites] Am J Surg Pathol. 2003 Nov;27(11):1473-6 [14576483.001]

[Cites] Leuk Lymphoma. 2004 Sep;45(9):1881-5 [15223650.001]

[Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]

[Cites] Ann Intern Med. 2005 Aug 16;143(4):265-73 [16103470.001]

[Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]

[Cites] Br J Dermatol. 2005 Oct;153(4):828-32 [16181470.001]

[Cites] Blood. 2006 May 15;107(10):3832-40 [16410446.001]

[Cites] J Clin Oncol. 2006 Sep 1;24(25):4123-8 [16896005.001]

[Cites] J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):167-73 [17117144.001]

[Cites] Haematologica. 2007 Jan;92(1):e11-2 [17405744.001]

[Cites] J Oral Maxillofac Surg. 2007 Jul;65(7):1361-4 [17577503.001]

[Cites] Am J Hematol. 2007 Aug;82(8):761-5 [17094093.001]

[Cites] Am J Hematol. 2008 Oct;83(10):804-9 [18756521.001]

[Cites] Oral Dis. 2009 Jan;15(1):38-45 [18939960.001]

[Cites] Intern Med. 2009;48(7):559-62 [19336959.001]

[Cites] Eur J Haematol. 2009 Jun;82(6):490-2 [19220417.001]

[Cites] Blood. 2009 Jun 11;113(24):6069-76 [19380866.001]

[Cites] AIDS. 2009 Sep 24;23(15):2029-37 [19531926.001]

[Cites] Am J Clin Pathol. 2009 Oct;132(4):597-605 [19762538.001]

[Cites] Blood. 2009 Oct 22;114(17):3533-7 [19704118.001]

[Cites] Oral Oncol. 2002 Jan;38(1):96-102 [11755827.001]

(PMID = 20167839.001).

[ISSN] 1549-490X

[Journal-full-title] The oncologist

[ISO-abbreviation] Oncologist

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol

[Other-IDs] NLM/ PMC3227958

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors.

OBJECTIVES: To assess complete remission (CR) and survival in patients with systemic AIDS-related non-Hodgkin lymphoma (ARL) receiving highly active antiretroviral therapy (HAART).

Histologic subtypes were diffuse large B-cell lymphoma (DLCL; n = 153 [72.9%]), Burkitt and atypical Burkitt/Burkitt-like lymphoma (BL; n = 40 [19.0%]), T-cell lymphoma (TC; n = 8 [3.8%]), and miscellaneous (n = 9 [4.3%]).

CONCLUSIONS: In patients with ARL treated with HAART, CR was associated exclusively with tumor-related factors.

[MeSH-major] Anti-HIV Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / pathology

[MeSH-minor] Adult. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / pathology. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Longitudinal Studies. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Male. Middle Aged. Prognosis. Remission Induction. Statistics as Topic. Survival Analysis

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17117144.001).

[ISSN] 1525-4135

[Journal-full-title] Journal of acquired immune deficiency syndromes (1999)

[ISO-abbreviation] J. Acquir. Immune Defic. Syndr.

[Language] eng

[Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Anti-HIV Agents

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] HIV lumbosacral radiculoplexus neuropathy mimicking lymphoma: diffuse infiltrative lymphocytosis syndrome (DILS) restricted to nerve?

Diffuse infiltrative lymphocytosis syndrome (DILS) is a hyperimmune reaction against HIV.

It leads to MHC-restricted clonal expansion of CD8 T cells characterized by circulating CD8 hyperlymphocytosis and CD8 T-cell infiltration in organs.

Nerve biopsy showed large collections of CD8 lymphocytes suspicious for lymphoma.

[MeSH-major] AIDS-Associated Nephropathy / diagnosis. Lymphocytosis / diagnosis. Lymphoma, AIDS-Related / diagnosis. Radiculopathy / diagnosis

Genetic Alliance. consumer health - HIV.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Muscle Nerve. 2002 Apr;25(4):477-91 [11932965.001]

[Cites] J Neuropathol Exp Neurol. 2008 Aug;67(8):819-27 [18648321.001]

[Cites] Mayo Clin Proc. 1975 Nov;50(11):621-37 [1186294.001]

[Cites] Ann Neurol. 1980 Dec;8(6):590-6 [7212646.001]

[Cites] Ann Neurol. 1987 Jan;21(1):32-40 [3030188.001]

[Cites] Cancer. 1988 Jun 1;61(11):2318-24 [3365659.001]

[Cites] Lancet. 1989 Aug 26;2(8661):466-8 [2570184.001]

[Cites] Ann Intern Med. 1990 Jan 1;112(1):3-10 [2136714.001]

[Cites] Rheum Dis Clin North Am. 1992 Aug;18(3):683-97 [1496168.001]

[Cites] J Clin Invest. 1993 Jul;92(1):495-502 [8392093.001]

[Cites] Ann Neurol. 1994 Jan;35(1):53-8 [8285593.001]

[Cites] AIDS. 1996 Apr;10(4):385-91 [8728042.001]

[Cites] Ann Neurol. 1997 Apr;41(4):438-45 [9124800.001]

[Cites] Neurology. 1998 Apr;50(4):855-7 [9566362.001]

[Cites] Neurology. 1998 Apr;50(4):1041-4 [9566392.001]

[Cites] Mayo Clin Proc. 2006 Feb;81(2):213-9 [16471077.001]

[Cites] Neuromuscul Disord. 2004 Nov;14(11):740-3 [15482959.001]

(PMID = 19882634.001).

[ISSN] 1097-4598

[Journal-full-title] Muscle & nerve

[ISO-abbreviation] Muscle Nerve

[Language] eng

[Grant] United States / NINDS NIH HHS / NS / R01 NS036797; United States / NINDS NIH HHS / NS / R01 NS036797-12

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Other-IDs] NLM/ NIHMS235321; NLM/ PMC2965045

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] HIV-1 Tat mimetic of VEGF correlates with increased microvessels density in AIDS-related diffuse large B-cell and Burkitt lymphomas.

We evaluated the role of HIV-1 Tat in regulating the level of VEGF expression and microvessel density in the AIDS-related diffuse large B-cell (DLBCL) and Burkitt lymphomas (BL).

Reduced VEGF protein expression in primary HIV-1 positive BL and DLBCL, compared to the negative cases, supported the findings of promoter downregulation from the cell lines.

Thus, targeting Tat protein itself and stabilizing transient silencing of VEGF expression or use of monoclonal antibodies against their receptors in the AIDS-associated tumors will open a window for future explorable pathways in the management of angiogenic phenotypes in the AIDS-associated non-Hodgkin's lymphomas.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nat Med. 1996 Dec;2(12):1371-5 [8946838.001]

[Cites] Oncogene. 2000 Jan 20;19(3):373-9 [10656684.001]

[Cites] Oncogene. 1996 Jan 18;12(2):289-97 [8570206.001]

[Cites] Nature. 1995 Jul 6;376(6535):66-70 [7596436.001]

[Cites] Leuk Lymphoma. 2007 Oct;48(10):2014-21 [17917969.001]

[Cites] Br J Cancer. 2007 Jul 16;97(2):223-30 [17595666.001]

[Cites] Exp Cell Res. 2007 May 1;313(8):1561-74 [17382929.001]

[Cites] Am J Pathol. 2007 Apr;170(4):1362-9 [17392174.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4647-52 [17360578.001]

[Cites] Biochem Biophys Res Commun. 2007 Apr 13;355(3):693-9 [17320821.001]

[Cites] Nat Struct Mol Biol. 2007 Mar;14(3):249-50 [17293873.001]

[Cites] J Cell Biochem. 2007 Feb 15;100(3):727-37 [17115409.001]

[Cites] Curr Med Chem. 2006;13(16):1845-57 [16842197.001]

[Cites] FEBS J. 2005 Nov;272(22):5723-41 [16279938.001]

[Cites] Folia Histochem Cytobiol. 2004;42(4):241-3 [15704651.001]

[Cites] Biochem Pharmacol. 2004 Dec 15;68(12):2359-66 [15548382.001]

[Cites] Circulation. 1997 Dec 2;96(11):4083-94 [9403634.001]

[Cites] J Biol Chem. 1998 Nov 20;273(47):31119-24 [9813014.001]

[Cites] Science. 1998 Dec 4;282(5395):1837-9 [9874635.001]

[Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3851-6 [9520456.001]

[Cites] J Clin Pathol. 1997 Jun;50(6):481-4 [9378813.001]

[Cites] Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):233-5 [7542074.001]

[Cites] Cancer Res. 1995 Sep 15;55(18):3964-8 [7664263.001]

[Cites] Nature. 1994 Oct 20;371(6499):674-80 [7935812.001]

[Cites] Arch Orthop Trauma Surg. 2003 Nov;123(9):475-80 [12750926.001]

[Cites] Angiogenesis. 2002;5(3):141-51 [12831055.001]

[Cites] Cell Prolif. 2003 Jun;36(3):131-49 [12814430.001]

[Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]

[Cites] Curr Drug Targets Infect Disord. 2003 Jun;3(2):115-28 [12769789.001]

[Cites] J Rheumatol. 2003 Feb;30(2):260-8 [12563678.001]

[Cites] J Clin Oncol. 2002 Nov 1;20(21):4368-80 [12409337.001]

[Cites] Hum Pathol. 2002 Jul;33(7):723-31 [12196924.001]

[Cites] Cancer Control. 2002 Mar-Apr;9(2 Suppl):36-44 [11965229.001]

[Cites] Clin Microbiol Rev. 2002 Apr;15(2):310-26 [11932235.001]

[Cites] Am J Clin Pathol. 2001 Dec;116(6):838-45 [11764072.001]

[Cites] Biochem J. 2001 Feb 1;353(Pt 3):569-78 [11171054.001]

[Cites] Cancer Res. 2001 Jan 15;61(2):462-8 [11212232.001]

[Cites] Curr Opin Oncol. 2000 Sep;12(5):445-9 [10975552.001]

[Cites] Biochem Biophys Res Commun. 2000 Jun 24;273(1):267-71 [10873597.001]

[Cites] Oncologist. 2000;5 Suppl 1:3-10 [10804084.001]

[Cites] Am J Pathol. 1996 Apr;148(4):1065-74 [8644848.001]

(PMID = 19669199.001).

[ISSN] 1868-9256

[Journal-full-title] Journal of hematopathology

[ISO-abbreviation] J Hematop

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

[Other-IDs] NLM/ PMC2712328

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Recurrent lymphoma presenting as a penile ulcer in a patient with AIDS.

Penile lymphoma is a rare neoplasm.

We report a 45-year-old man with history of AIDS and previous retroperitoneal lymphoma who presented with painless penile ulceration and multiple inguinal lymphadenopathy.

Fine needle biopsy showed diffuse, large B-cell lymphoma.

We review the literature and discuss this uncommon presentation of lymphoma.

[MeSH-major] Lymphoma, AIDS-Related / pathology. Neoplasm Recurrence, Local / pathology. Penile Diseases / etiology. Penile Diseases / pathology. Penile Neoplasms / etiology. Penile Neoplasms / pathology. Ulcer / etiology. Ulcer / pathology

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - Penis Disorders.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16150237.001).

[ISSN] 1087-2108

[Journal-full-title] Dermatology online journal

[ISO-abbreviation] Dermatol. Online J.

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] United States

[Number-of-references] 13

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Oral cavity lymphoma as secondary AIDS-defining neoplasm in a patient on HAART with immune reconstitution.

Lymphomas of the oral cavity are a rare complication of advanced HIV/AIDS disease.

We report the case of a patient with AIDS who developed diffuse large B-cell non-Hodgkins lymphoma of the oral cavity during highly active antiretroviral therapy, with undetectable plasma viral load and immune reconstitution.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Mouth Neoplasms / diagnosis

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

MedlinePlus Health Information. consumer health - Oral Cancer.

HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17992417.001).

[ISSN] 0037-8682

[Journal-full-title] Revista da Sociedade Brasileira de Medicina Tropical

[ISO-abbreviation] Rev. Soc. Bras. Med. Trop.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Brazil

[Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy.

PURPOSE: To compare the prognostic factors for survival and the validity of the International Prognostic Index (IPI) in patients with HIV-related diffuse large-cell lymphoma (HIV-DLCL) treated with curative intent in the pre-highly active antiretroviral therapy (HAART) era versus the HAART era.

RESULTS: There were no statistically significant differences in terms of either lymphoma or HIV-related characteristics in the two time periods.

Clinical outcomes in patients with HIV-DLCL are now approaching the outcomes of patients with de novo lymphoma.

[MeSH-major] Antiretroviral Therapy, Highly Active. Health Status Indicators. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / drug therapy

Genetic Alliance. consumer health - Lymphoma, large-cell.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16230675.001).

[ISSN] 0732-183X

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Genome wide DNA-profiling of HIV-related B-cell lymphomas.

To elucidate HIV-NHL pathogenesis, we performed a genome-wide DNA profiling based on a single nucleotide polymorphism-based microarray comparative genomic hybridization in 57 HIV-lymphomas and, for comparison, in 105 immunocompetent diffuse large B-cell lymphomas (IC-DLBCL).

HIV-Burkitt lymphoma showed a significantly lower number of lesions than HIV-DLBCL (P = 0.032), whereas the median number of copy number changes was significantly higher in Epstein-Barr virus negative (EBV-) HIV-DLBCL (42.5, range 8-153) compared to EBV+ cases (22; range 3-41; P = 0.029).

[MeSH-major] Lymphoma, AIDS-Related / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Polymorphism, Single Nucleotide

[MeSH-minor] Burkitt Lymphoma / genetics. Chromosome Aberrations. DNA Methylation. Gene Frequency. Humans. Microarray Analysis. Polymerase Chain Reaction / methods

Genetic Alliance. consumer health - B-Cell Lymphomas.

Genetic Alliance. consumer health - HIV.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Oncogene. 2004 Dec 2;23(56):9148-54 [15480422.001]

[Cites] Br J Haematol. 2006 Jul;134(1):27-36 [16803564.001]

[Cites] Cancer Lett. 2006 Jan 28;232(1):37-47 [16242840.001]

[Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]

[Cites] Semin Cancer Biol. 2007 Feb;17(1):31-41 [17140807.001]

[Cites] Cancer Lett. 2007 Jul 18;252(2):157-70 [17188425.001]

[Cites] Blood. 2003 Nov 15;102(10):3775-85 [12907442.001]

[Cites] Blood. 2008 Feb 15;111(4):2347-53 [18079361.001]

[Cites] Cancer Lett. 2006 Jan 28;232(1):48-57 [16221525.001]

[Cites] Am J Hum Genet. 1992 Jun;50(6):1243-51 [1317992.001]

[Cites] Haematologica. 2008 Aug;93(8):1178-85 [18556404.001]

[Cites] J Biol Chem. 2006 Mar 31;281(13):8591-9 [16455660.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3615-20 [11891319.001]

[Cites] AIDS. 2006 Nov 28;20(18):2285-91 [17117014.001]

[Cites] Int J Cancer. 2005 Sep 1;116(3):407-14 [15818620.001]

[Cites] Blood. 2005 Nov 1;106(9):3183-90 [16046532.001]

[Cites] J Cell Physiol. 2007 Aug;212(2):307-10 [17458891.001]

[Cites] Oncogene. 2003 Feb 27;22(8):1225-37 [12606949.001]

[Cites] Mol Cancer Res. 2003 Nov;1(13):940-7 [14638866.001]

[Cites] N Engl J Med. 2008 Nov 27;359(22):2313-23 [19038878.001]

[Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]

[Cites] Front Biosci. 2007 Sep 01;12:4911-24 [17569619.001]

[Cites] Blood. 2006 Mar 15;107(6):2477-85 [16317097.001]

[Cites] Cancer Res. 2004 Sep 1;64(17):5948-55 [15342373.001]

[Cites] J Clin Pathol. 2007 Dec;60(12):1365-72 [18042692.001]

[Cites] Nat Cell Biol. 2003 Mar;5(3):216-23 [12598906.001]

[Cites] Nature. 2009 Jun 4;459(7247):717-21 [19412164.001]

[Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]

[Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]

[Cites] PLoS Comput Biol. 2006 May;2(5):e41 [16699594.001]

[Cites] Nat Rev Cancer. 2004 Dec;4(12):978-87 [15573119.001]

[Cites] Eur J Cancer. 2001 Jul;37(10):1270-5 [11423258.001]

[Cites] Genes Chromosomes Cancer. 2007 Dec;46(12):1129-36 [17823927.001]

[Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5 [18765795.001]

[Cites] Cancer Res. 2008 Apr 15;68(8):2610-21 [18375840.001]

[Cites] Cell Cycle. 2007 May 2;6(9):1044-8 [17457056.001]

[Cites] BMC Bioinformatics. 2009 Jan 08;10:10 [19133123.001]

[Cites] Int J Cancer. 2006 Apr 15;118(8):1945-53 [16287063.001]

[Cites] Cancer Res. 2001 Nov 15;61(22):8068-73 [11719429.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10399-404 [12925741.001]

[Cites] Biochem Biophys Res Commun. 2001 May 25;283(5):1031-6 [11355876.001]

[Cites] Genes Chromosomes Cancer. 2004 Dec;41(4):321-9 [15384174.001]

[Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10 ):5956-61 [12719539.001]

[Cites] Nat Rev Immunol. 2009 Apr;9(4):235-45 [19319142.001]

[Cites] Br J Haematol. 2008 May;141(5):622-30 [18397341.001]

[Cites] Oncogene. 2005 Feb 24;24(9):1625-33 [15674328.001]

[Cites] Blood. 2009 Feb 5;113(6):1213-24 [18955561.001]

[Cites] Lab Invest. 2004 Sep;84(9):1193-9 [15241441.001]

[Cites] Cell Death Differ. 2005 Aug;12(8):1031-43 [16015380.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3949-54 [17360458.001]

[Cites] Cancer Cell. 2006 Apr;9(4):313-25 [16616336.001]

[Cites] Cancer Genet Cytogenet. 2006 Dec;171(2):119-21 [17116491.001]

[Cites] J Neurochem. 2008 Jun;105(5):1806-19 [18248624.001]

(PMID = 19832807.001).

[ISSN] 1365-2141

[Journal-full-title] British journal of haematology

[ISO-abbreviation] Br. J. Haematol.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / U01 CA114778; United States / NCI NIH HHS / CA / U01 CA114778-05; United States / NCI NIH HHS / CA / UO1 CA 114778

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

[Publication-country] England

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Soft tissue non-Hodgkin lymphoma of shoulder in a HIV patient: a report of a case and review of the literature.

BACKGROUND: The risk of developing lymphoma is greatly increased in HIV infection.

HIV-related neoplastic processes that affect the musculoskeletal system include Kaposi's sarcoma and non-Hodgkin's lymphoma, the latter being mainly localized at lower extremities, spine and skull.

A final diagnosis of diffuse large B-cell lymphoma was made.

CONCLUSION: In this report, we present a case of diffuse large B-cell lymphoma localized in the soft tissue of the shoulder in a HIV infected patient.

[MeSH-major] Lymphoma, AIDS-Related / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Pregnancy Complications, Neoplastic / pathology. Pregnancy Outcome. Soft Tissue Neoplasms / pathology

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Ann Med Interne (Paris). 2003 Dec;154(8):523-8 [15037828.001]

[Cites] J Am Acad Dermatol. 2003 May;48(5 Suppl):S82-5 [12734486.001]

[Cites] Radiology. 1980 Feb;134(2):521-3 [7352243.001]

[Cites] Am J Surg Pathol. 1987 May;11(5):359-66 [3578646.001]

[Cites] Br J Radiol. 1989 Jan;62(733):81 [2914198.001]

[Cites] J Comput Assist Tomogr. 1995 May-Jun;19(3):455-9 [7790558.001]

[Cites] Bol Asoc Med P R. 1995 Oct-Dec;87(10-12):158-61 [8924158.001]

[Cites] Crit Rev Diagn Imaging. 1996 Sep;37(4):305-47 [8894398.001]

[Cites] Clin Radiol. 1997 Mar;52(3):203-12 [9091255.001]

[Cites] Radiol Clin North Am. 1997 Sep;35(5):1167-89 [9298091.001]

[Cites] Am J Orthop (Belle Mead NJ). 1998 Feb;27(2):128-34 [9506198.001]

[Cites] Semin Ultrasound CT MR. 1998 Apr;19(2):200-8 [9567324.001]

[Cites] Blood. 1998 Aug 1;92(3):1011-9 [9680371.001]

[Cites] Am J Surg Pathol. 1999 Jan;23(1):88-96 [9888708.001]

[Cites] Clin Orthop Relat Res. 1999 Mar;(360):221-30 [10101328.001]

[Cites] Leuk Lymphoma. 2006 Feb;47(2):329-32 [16321866.001]

[Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]

[Cites] Leukemia. 2007 Feb;21(2):207-14 [17170731.001]

[Cites] AJR Am J Roentgenol. 2007 Jun;188(6):1443-5 [17515361.001]

[Cites] J Am Acad Orthop Surg. 2002 Sep-Oct;10(5):312-20 [12374482.001]

[Cites] Rev Chir Orthop Reparatrice Appar Mot. 2002 Sep;88(5):518-21 [12399719.001]

[Cites] Leuk Lymphoma. 2002 Dec;43(12):2405-7 [12613532.001]

[Cites] Skeletal Radiol. 2004 Jun;33(6):311-20 [15127244.001]

(PMID = 18939988.001).

[ISSN] 1477-7819

[Journal-full-title] World journal of surgical oncology

[ISO-abbreviation] World J Surg Oncol

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] England

[Number-of-references] 24

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [HIV-related multiple non-Hodgkin lymphomas].

He was HIV-positive, and had gastric diffuse large B-cell lymphoma and renal T-cell anaplastic large cell lymphoma (T-ALCL).

We diagnosed double lymphomas related to AIDS.

Biopsy specimen demonstrated null cell ALCL, and this patient demonstrated multiple lymphomas.

[MeSH-major] Lymphoma, AIDS-Related / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, T-Cell / diagnosis. Neoplasms, Multiple Primary. Stomach Neoplasms / diagnosis

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - Stomach Cancer.

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISOLONE .

Hazardous Substances Data Bank. VINCRISTINE .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19047787.001).

[ISSN] 0485-1439

[Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology

[ISO-abbreviation] Rinsho Ketsueki

[Language] jpn

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Successful treatment with autologous peripheral blood stem cell transplantation for acquired immunodeficiency syndrome (AIDS)-related malignant lymphoma.

Histologic diagnosis of a biopsied lymph node was diffuse, large, B cell-type malignant lymphoma.

The karyotype of the lymphoma cells was t(8;14)(q24;q32), which was confirmed by G-banding and fluorescent in situ hybridization.

The clinical stage of the lymphoma was IVB and the international prognosis index was categorized as high.

Complete remission (CR) of the lymphoma was obtained after 2 courses of CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone) chemotherapy and 4 subsequent courses of rituximab-combined CHOP (R-CHOP).

Because of the poor prognosis of AIDS-related lymphoma, he received autologous peripheral blood stem cell transplantation with the MEAM protocol (ranimustine, etoposide, cytarabine, melphalan) as a conditioning procedure without a severe infectious episode.

[MeSH-major] Lymphoma, AIDS-Related / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Peripheral Blood Stem Cell Transplantation

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Transplantation.

Hazardous Substances Data Bank. RITUXIMAB .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISOLONE .

Hazardous Substances Data Bank. VINCRISTINE .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20009441.001).

[ISSN] 0485-1439

[Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology

[ISO-abbreviation] Rinsho Ketsueki

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Plasmablastic lymphoma: a review.

Plasmablastic lymphoma (PBL) has been recently characterised as an aggressive subtype of non-Hodgkin's lymphoma, most frequently arising in the oral cavity of HIV-infected patients.

PBLs are composed of large cells with eccentrically located nuclei and deeply basophilic cytoplasm with a paranuclear hof.

The tumour cells are invariably immunoreactive for the plasma cell marker CD138, and show monoclonal rearrangement of the immunoglobulin heavy chain gene (IgH) and/or clonal restriction of the Ig light chain (IgL) gene expression in most of the cases.

Similar to other types of AIDS-related lymphomas, there is evidence that Epstein-Barr virus and Kaposi-sarcoma associated Human Herpes Virus 8 may play a relevant role in the pathogenesis of PBL.

[MeSH-major] Lymphoma, AIDS-Related / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Mouth Neoplasms / pathology

MedlinePlus Health Information. consumer health - Oral Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18939960.001).

[ISSN] 1601-0825

[Journal-full-title] Oral diseases

[ISO-abbreviation] Oral Dis

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Denmark

[Chemical-registry-number] 0 / SDC1 protein, human; 0 / Syndecan-1

[Number-of-references] 54

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Role of molecular subtype in predicting outcome of AIDS-related diffuse large B-cell lymphoma.

[MeSH-major] Lymphoma, AIDS-Related / genetics. Lymphoma, AIDS-Related / pathology. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentOn] J Clin Oncol. 2009 Oct 20;27(30):5039-48 [19752343.001]

(PMID = 20421532.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Comment; Letter

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Pathology of AIDS-related lymphadenopathy: a study of 18 biopsy cases].

OBJECTIVE: To study the clinicopathologic features of acquired immunodeficiency syndrome (AIDS)-related lymphadenopathy and to elucidate the salient features helpful in achieving a correct pathologic differentiated diagnosis.

METHODS: Eighteen cases of AIDS-related lymphadenopathy were retrieved from the files of the First Affiliated Hospital of Guangxi Medical University from 2001 to 2004.

The remaining patient was complicated with diffuse large B-cell lymphoma.

CONCLUSIONS: When presented in early stages, AIDS-related lymphadenopathy may be overlooked, especially in routine pathology practice.

Florid infection with Penicillium marneffei is also considered as an important predictor for underlying AIDS.

Thorough understanding of morphologic features of AIDS-related lymphadenopathy, including possible co-infection, is essential in arriving at the correct diagnosis.

[MeSH-major] AIDS-Related Complex / pathology. AIDS-Related Opportunistic Infections / pathology. Lymph Nodes / pathology

[MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Lymphoma, AIDS-Related / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Mycobacterium / isolation & purification. Mycobacterium Infections / microbiology. Mycobacterium Infections / pathology. Mycoses / microbiology. Mycoses / pathology. Penicillium / isolation & purification. Retrospective Studies

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16545184.001).

[ISSN] 0529-5807

[Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology

[ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article

[Publication-country] China

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Recurrent chromosomal alterations in molecularly classified AIDS-related lymphomas: an integrated analysis of DNA copy number and gene expression.

HIV-infected individuals have a significantly increased risk of developing an aggressive B-cell Non-Hodgkin Lymphoma relative to HIV(-) persons.

Due to their aggressive nature, AIDS-related lymphomas (ARL) can also be more difficult to classify.

To aid in case classification and identify key pathogenetic events in ARL, we analyzed gene expression data and somatic DNA copy number changes by high-resolution array comparative genomic hybridization in tumors from 20 B-cell derived ARL (B-ARL) patients.

Gene expression-based predictors robustly classified the B-ARL cases, distinguishing Burkitt lymphoma and diffuse large B-cell lymphoma, and identifying activated B-cell like and germinal center B-cell like molecular subtypes of diffuse large B-cell lymphoma.

[MeSH-major] Chromosome Aberrations. Gene Dosage. Gene Expression. HIV Infections / complications. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / pathology

[MeSH-minor] Adult. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / pathology. Comparative Genomic Hybridization. Diagnosis, Differential. Female. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Young Adult

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

SciCrunch. ArrayExpress: Data: Microarray .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20216076.001).

[ISSN] 1944-7884

[Journal-full-title] Journal of acquired immune deficiency syndromes (1999)

[ISO-abbreviation] J. Acquir. Immune Defic. Syndr.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / 5U01/CA114778; United States / NCI NIH HHS / CA / 5U01/CA114778-02S1; United States / NCRR NIH HHS / RR / P20 RR016469; United States / NCI NIH HHS / CA / U01/CA84967

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Non-Hodgkin's lymphoma in the elderly.

The expansion of older population segments and the continuous increase in the incidence of non-Hodgkin's lymphoma (NHL) makes this group of neoplasms an important and growing problem.

Older NHL patients have increased risk of therapy-related toxicity as a result of age-related physiological changes and frequent co-morbidities.

The comprehensive geriatric assessment (CGA) is one multidisciplinary tool that has been applied successfully to older cancer patients and aids in identification of subjects who will or will not benefit from anti-neoplastic treatment.

Diffuse large B-cell lymphoma is an aggressive but potentially curable disease.

Salvage chemotherapy followed by autologous haematopoietic cell transplant (autoHCT) has been shown to have better failure-free and overall survival in randomized trials involving younger patients.

Highly selected individuals up to age 70 years may attain long-term survival benefit from autoHCT, although transplant-related mortality is higher than in younger patients.

[MeSH-major] Aging / physiology. Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / physiopathology. Lymphoma, Non-Hodgkin / therapy

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

MedlinePlus Health Information. consumer health - Seniors' Health.

Hazardous Substances Data Bank. RITUXIMAB .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 2005 Aug 1;23(22):5019-26 [15983392.001]

[Cites] Blood. 2008 Jun 15;111(12 ):5486-95 [18390837.001]

[Cites] Clin Pharmacokinet. 2003;42(9):779-91 [12882586.001]

[Cites] Semin Oncol. 2002 Feb;29(1S2):25-29 [28140088.001]

[Cites] Oncology (Williston Park). 2007 Aug;21(9):1104-10 [17910313.001]

[Cites] Clin Pharmacokinet. 1996 Jul;31(1):47-64 [8827399.001]

[Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]

[Cites] J Clin Oncol. 2007 Mar 1;25(7):787-92 [17228021.001]

[Cites] J Clin Oncol. 2001 Jan 15;19(2):389-97 [11208830.001]

[Cites] J Clin Oncol. 2004 Aug 1;22(15):3032-8 [15210738.001]

[Cites] Best Pract Res Clin Haematol. 2005 Mar;18(1):81-95 [15694186.001]

[Cites] Blood. 1990 Oct 1;76(7):1293-8 [2207307.001]

[Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]

[Cites] Blood. 2004 Aug 1;104(3):634-41 [15016643.001]

[Cites] Cancer. 2008 May 15;112(10):2228-32 [18338745.001]

[Cites] Eur J Haematol. 2008 Feb;80(2):127-32 [18005385.001]

[Cites] Crit Rev Oncol Hematol. 2008 Oct;68 Suppl 1:S1-8 [18752969.001]

[Cites] J Clin Oncol. 2006 Jul 1;24(19):3187-205 [16682719.001]

[Cites] Eur J Cancer. 2003 May;39(7):870-80 [12706355.001]

[Cites] J Clin Oncol. 2009 Jun 20;27(18):3036-43 [19414675.001]

[Cites] J Clin Oncol. 1995 Jul;13(7):1726-33 [7602362.001]

[Cites] J Clin Oncol. 2009 Aug 10;27(23):3822-9 [19581539.001]

[Cites] Blood. 2002 Sep 1;100(5):1559-65 [12176870.001]

[Cites] Curr Treat Options Oncol. 2006 Jul;7(4):285-94 [16916489.001]

[Cites] Lancet Oncol. 2006 May;7(5):357-9 [16648037.001]

[Cites] J Clin Oncol. 2004 Apr 15;22(8):1454-9 [15024027.001]

[Cites] Blood. 2005 Feb 15;105(4):1417-23 [15494430.001]

[Cites] Oncology (Williston Park). 2007 Sep;21(10):1191-8; discussion 1198-1208, 1210 [17926798.001]

[Cites] Blood. 2005 May 15;105(10):3817-23 [15687232.001]

[Cites] Crit Rev Oncol Hematol. 2000 Feb;33(2):119-28 [10737373.001]

[Cites] Am J Geriatr Pharmacother. 2008 Aug;6(3):153-60 [18775390.001]

[Cites] Cancer Control. 2007 Jan;14(1):44-56 [17242670.001]

[Cites] Crit Rev Oncol Hematol. 2005 Sep;55(3):241-52 [16084735.001]

[Cites] Ann Oncol. 2007 Jul;18(7):1216-23 [17470451.001]

[Cites] J Clin Oncol. 2004 Nov 1;22(21):4302-11 [15381684.001]

[Cites] Blood. 2006 Jan 1;107(1):265-76 [16150940.001]

[Cites] Ann Oncol. 2009 Mar;20(3):520-5 [19074748.001]

[Cites] Semin Hematol. 1999 Apr;36(2):115-27 [10319380.001]

[Cites] J Clin Oncol. 2003 Nov 1;21(21):3918-27 [14517188.001]

[Cites] Br J Haematol. 2005 May;129(3):366-72 [15842660.001]

[Cites] Leuk Lymphoma. 2008;49 Suppl 1:43-51 [18821432.001]

[Cites] J Clin Oncol. 2007 Jul 20;25(21):3158-67 [17634496.001]

[Cites] Br J Haematol. 2009 May;145(3):344-9 [19245430.001]

[Cites] J Clin Oncol. 2004 Aug 1;22(15):2982-4 [15210737.001]

[Cites] Clin Lymphoma Myeloma. 2007 Dec;8 Suppl 2:S43-9 [18284715.001]

[Cites] Bull Cancer. 2008 May 28;95 FMC Onco:F79-83 [18511372.001]

[Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]

[Cites] Leuk Lymphoma. 1999 Jul;34(3-4):273-85 [10439364.001]

[Cites] J Clin Oncol. 2008 Jan 10;26(2):204-10 [18182663.001]

[Cites] Am J Health Syst Pharm. 2007 Mar 15;64(6):652-60 [17353576.001]

[Cites] J Clin Oncol. 2002 May 15;20(10 ):2453-63 [12011122.001]

[Cites] N Engl J Med. 1992 Oct 22;327(17):1209-15 [1406793.001]

[Cites] Blood. 2004 Sep 1;104(5):1258-65 [15126323.001]

[Cites] J Clin Oncol. 2009 Mar 10;27(8):1209-13 [19188674.001]

[Cites] J Clin Oncol. 2005 Jul 1;23(19):4390-8 [15994148.001]

[Cites] J Clin Oncol. 2000 Apr;18(7):1412-22 [10735888.001]

[Cites] Aging Clin Exp Res. 2005 Jun;17(3):181-5 [16110729.001]

[Cites] J Clin Oncol. 2008 Sep 20;26(27):4473-9 [18626004.001]

[Cites] Leukemia. 2007 Nov;21(11):2324-31 [17637813.001]

[Cites] Bone Marrow Transplant. 2000 May;25(9):957-64 [10800063.001]

[Cites] J Immunol. 2009 Jul 1;183(1):749-58 [19535640.001]

[Cites] J Clin Oncol. 2006 May 1;24(13):2105-12 [16606971.001]

[Cites] J Clin Oncol. 2008 Oct 1;26(28):4579-86 [18662969.001]

[Cites] Cancer. 1983 Aug 1;52(3):393-8 [6344979.001]

[Cites] J Clin Oncol. 2009 Apr 1;27(10):1607-14 [19255334.001]

[Cites] Clin Geriatr Med. 1997 May;13(2):251-63 [9115450.001]

[Cites] J Clin Oncol. 1997 Aug;15(8):2945-53 [9256139.001]

[Cites] N Engl J Med. 1993 Sep 30;329(14):1046 [8366915.001]

[Cites] Biol Blood Marrow Transplant. 2008 Dec;14(12):1323-33 [19041053.001]

[Cites] Cochrane Database Syst Rev. 2008 Oct 08;(4):CD003189 [18843642.001]

[Cites] J Clin Oncol. 2006 Aug 20;24(24):3880-6 [16864854.001]

[Cites] J Clin Oncol. 2005 Mar 20;23(9):1984-92 [15668467.001]

[Cites] Blood. 2006 Dec 15;108(13):4003-8 [16946304.001]

[Cites] Haematologica. 2002 Jan;87(1):33-43 [11801463.001]

[Cites] Blood. 2005 Apr 1;105(7):2677-84 [15591112.001]

[Cites] Br J Haematol. 2008 Jun;142(2):149-65 [18410453.001]

[Cites] J Clin Oncol. 2005 Aug 10;23(23):5347-56 [15983389.001]

[Cites] J Clin Oncol. 2003 Sep 1;21(17):3214-9 [12874269.001]

[Cites] Cancer. 1976 Oct;38(4):1484-93 [791473.001]

[Cites] J Clin Oncol. 1986 Mar;4(3):295-305 [3512783.001]

[Cites] Hematol Oncol. 1989 Sep-Oct;7(5):365-80 [2670728.001]

[Cites] Ann Hematol. 2001 Jul;80(7):398-405 [11529465.001]

[Cites] Blood. 2003 May 15;101(10):3840-8 [12531794.001]

[Cites] J Am Geriatr Soc. 2001 Dec;49(12):1691-9 [11844005.001]

[Cites] Br J Haematol. 2007 Jan;136(2):191-202 [17073892.001]

[Cites] J Clin Oncol. 2005 Nov 20;23(33):8447-52 [16230674.001]

[Cites] N Engl J Med. 2005 Mar 24;352(12):1197-205 [15788496.001]

[Cites] J Clin Oncol. 2007 Jun 20;25(18):2554-9 [17515573.001]

[Cites] Radiother Oncol. 1995 Sep;36(3):167-71 [8532901.001]

[Cites] Blood. 2004 May 15;103(10):3684-8 [14739217.001]

[Cites] Eur J Cancer. 2006 Oct;42(15):2433-53 [16750358.001]

[Cites] Clin Lymphoma. 2001 Jun;2(1):47-56 [11707870.001]

[Cites] Leuk Lymphoma. 2008;49 Suppl 1:59-66 [18821434.001]

[Cites] Blood. 2004 Oct 15;104(8):2269-71 [15166030.001]

[Cites] Blood. 1994 Oct 15;84(8):2726-32 [7919385.001]

[Cites] Semin Oncol. 1993 Feb;20(1):43-9 [8475409.001]

[Cites] Cancer. 2004 Oct 15;101(8):1835-42 [15386331.001]

[Cites] Ann Oncol. 2007 Jan;18(1):116-21 [16971665.001]

[Cites] Br J Haematol. 2003 Aug;122(3):413-23 [12877668.001]

[Cites] J Clin Oncol. 1994 Jun;12(6):1169-76 [8201379.001]

[Cites] Blood. 2004 Aug 1;104(3):626-33 [14982884.001]

[Cites] Blood. 1999 Jul 1;94(1):33-8 [10381495.001]

[Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]

[Cites] Ann Oncol. 2006 Sep;17 (9):1418-23 [16766582.001]

[Cites] Semin Hematol. 1988 Apr;25(2 Suppl 2):11-6 [2456618.001]

[Cites] N Engl J Med. 1998 Sep 24;339(13):900-5 [9744975.001]

[Cites] Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1219-27 [11728680.001]

[Cites] Expert Rev Anticancer Ther. 2008 Oct;8(10):1651-8 [18925856.001]

[Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]

[Cites] Ann Oncol. 2008 Jul;19(7):1327-30 [18349031.001]

[Cites] J Clin Oncol. 2005 Feb 1;23(4):667-75 [15613697.001]

[Cites] Lancet. 2003 Aug 16;362(9383):516-22 [12932382.001]

[Cites] Ann Intern Med. 2002 Jan 15;136(2):144-52 [11790067.001]

[Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):928-34 [16243446.001]

[Cites] Eur J Cancer. 2008 Mar;44(4):579-87 [18242077.001]

[Cites] J Clin Oncol. 2007 May 20;25(15):1986-92 [17420513.001]

[Cites] J Natl Cancer Inst. 2006 Sep 20;98(18):1292-301 [16985248.001]

[Cites] Cancer. 2003 Dec 15;98(12):2630-5 [14669282.001]

[Cites] Cancer Invest. 2007 Dec;25(8):766-75 [18058474.001]

[Cites] J Clin Oncol. 2008 Jul 1;26(19):3159-65 [18591554.001]

[Cites] Ann Oncol. 2008 Jun;19 Suppl 4:iv60-2 [18519407.001]

[Cites] Cancer Control. 2003 Nov-Dec;10(6):487-99 [14652525.001]

[Cites] J Clin Oncol. 2003 Jun 15;21(12):2407-14 [12805341.001]

[Cites] N Engl J Med. 1998 Jul 2;339(1):21-6 [9647875.001]

[Cites] Cancer Control. 1996 Oct;3(5 Suppl 1):5-14 [10765230.001]

[Cites] J Clin Oncol. 1997 Mar;15(3):1110-7 [9060552.001]

[Cites] Blood. 2004 Nov 1;104(9):2667-74 [15238420.001]

[Cites] J Natl Cancer Inst. 2007 May 2;99(9):706-14 [17470738.001]

[Cites] Bone Marrow Transplant. 2001 Mar;27(6):593-9 [11319588.001]

[Cites] J Clin Oncol. 2005 Feb 1;23(4):676-84 [15613699.001]

[Cites] Nephron. 1976;16(1):31-41 [1244564.001]

[Cites] J Clin Oncol. 2005 Feb 20;23(6):1088-95 [15657401.001]

[Cites] J Clin Oncol. 2002 Dec 15;20(24):4643-8 [12488408.001]

[Cites] J Clin Oncol. 2006 Apr 1;24(10):1582-9 [16575009.001]

[Cites] Lancet. 2009 Oct 31;374(9700):1512-20 [19767089.001]

[Cites] J Clin Oncol. 2002 Oct 15;20(20):4261-7 [12377971.001]

[Cites] J Clin Oncol. 1998 Jan;16(1):13-8 [9440717.001]

[Cites] J Clin Oncol. 2005 Oct 1;23(28):7013-23 [16145068.001]

[Cites] J Clin Oncol. 2005 May 20;23(15):3383-9 [15908650.001]

[Cites] Ann Oncol. 1995 Mar;6(3):257-62 [7612491.001]

[Cites] J Clin Oncol. 1996 Apr;14(4):1282-90 [8648385.001]

[Cites] Clin Cancer Res. 2008 Jan 1;14(1):309-17 [18172283.001]

[Cites] Hematol Oncol Clin North Am. 2008 Oct;22(5):941-52, ix [18954744.001]

[Cites] Hematol Oncol Clin North Am. 2008 Oct;22(5):1037-49, x-xi [18954750.001]

[Cites] Blood. 1997 May 1;89(9):3129-35 [9129015.001]

[Cites] J Clin Oncol. 1995 Oct;13(10):2530-9 [7595704.001]

[Cites] Semin Oncol. 2003 Feb;30(1S2):9-15 [28140221.001]

[Cites] J Clin Oncol. 2009 Mar 10;27(8):1202-8 [19204203.001]

[Cites] Blood. 2004 Nov 15;104(10):3064-71 [15284112.001]

[Cites] Cancer Control. 2007 Jan;14(1):7-12 [17242666.001]

[Cites] J Clin Oncol. 1998 Jul;16(7):2352-8 [9667250.001]

[Cites] Leuk Lymphoma. 2009 Jan;50(1):47-53 [19152172.001]

[Cites] Cancer. 2005 Nov 1;104(9):1998-2005 [16206252.001]

[Cites] Ann Hematol. 2007 Feb;86(2):95-100 [17031689.001]

[Cites] Nat Rev Cancer. 2009 Sep;9(9):675-81 [19701243.001]

[Cites] Curr Opin Oncol. 2008 Sep;20(5):502-8 [19106651.001]

[Cites] Bone Marrow Transplant. 2007 Nov;40(10):973-8 [17873917.001]

[Cites] Cancer. 1997 Oct 1;80(7):1302-10 [9317183.001]

[Cites] Blood. 2008 Feb 1;111(3):1094-100 [18003886.001]

[Cites] Haematologica. 2008 Dec;93(12):1837-42 [18838474.001]

[Cites] Blood. 2007 Mar 1;109(5):1857-61 [17105812.001]

[Cites] Ann Intern Med. 1990 May 1;112(9):699-706 [2334082.001]

[Cites] Drugs Aging. 2003;20(10):737-59 [12875610.001]

[Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]

[Cites] J Clin Oncol. 2002 Jan 15;20(2):494-502 [11786579.001]

[Cites] Eur J Cancer. 1998 Feb;34(3):329-36 [9640217.001]

[Cites] Gerontology. 1999 Sep-Oct;45(5):243-53 [10460985.001]

[Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]

[Cites] Haematologica. 2006 Jan;91(1):11-6 [16434365.001]

[Cites] J Clin Oncol. 2003 Aug 15;21(16):3051-9 [12837807.001]

[Cites] J Clin Oncol. 1998 Mar;16(3):859-63 [9508166.001]

[Cites] Ann Oncol. 1994;5 Suppl 2:67-71 [7515649.001]

[Cites] Blood. 2006 Nov 15;108(10):3295-301 [16873669.001]

[Cites] N Engl J Med. 1984 Dec 6;311(23):1471-5 [6548796.001]

[Cites] Hematol Oncol Clin North Am. 2008 Oct;22(5):863-82, viii [18954741.001]

[Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]

[Cites] J Clin Oncol. 1998 Jan;16(1):27-34 [9440719.001]

[Cites] Semin Radiat Oncol. 2007 Jul;17(3):169-75 [17591563.001]

[Cites] N Engl J Med. 2008 Aug 7;359(6):613-26 [18687642.001]

[Cites] Blood. 2006 Oct 15;108(8):2540-4 [16835383.001]

[Cites] J Clin Oncol. 2009 Mar 20;27(9):1492-501 [19224851.001]

[Cites] J Clin Oncol. 2003 Jan 1;21(1):5-15 [12506163.001]

[Cites] J Clin Oncol. 2004 Apr 15;22(8):1469-79 [15084620.001]

[Cites] Ann Oncol. 1997 Jul;8(7):675-80 [9296221.001]

[Cites] J Clin Oncol. 2006 Oct 20;24(30):4867-74 [17001068.001]

[Cites] J Natl Cancer Inst. 2009 Feb 18;101(4):248-55 [19211444.001]

[Cites] Blood. 2008 Oct 1;112(7):2687-93 [18625886.001]

[Cites] Blood. 2001 Jan 1;97(1):101-6 [11133748.001]

[Cites] Blood. 2002 Jun 15;99(12 ):4336-42 [12036859.001]

[Cites] Lancet Neurol. 2009 Jun;8(6):581-92 [19446277.001]

[Cites] Blood Rev. 2009 May;23(3):137-42 [18951668.001]

[Cites] Cancer Invest. 2006 Oct;24(6):593-600 [16982464.001]

[Cites] Cancer. 2006 Oct 1;107(7):1530-41 [16933332.001]

[Cites] Cancer Control. 2002 May-Jun;9(3):203-11 [12060818.001]

[Cites] Blood. 2001 Jan 15;97(2):404-9 [11154216.001]

[Cites] J Clin Oncol. 2003 Aug 15;21(16):3041-50 [12915593.001]

[Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]

[Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]

[Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1240-51 [10922409.001]

[Cites] Cancer. 2002 Apr 1;94(7):2015-23 [11932904.001]

[Cites] J Clin Oncol. 2008 Mar 20;26(9):1544-52 [18285605.001]

[Cites] J Clin Oncol. 2002 Feb 1;20(3):770-5 [11821460.001]

[Cites] Lancet Oncol. 2008 Feb;9(2):105-16 [18226581.001]

[Cites] J Clin Oncol. 1998 Dec;16(12):3803-9 [9850025.001]

[Cites] Blood. 2009 Apr 23;113(17):3896-902 [19144985.001]

[Cites] J Clin Oncol. 2009 Feb 1;27(4):511-8 [19075279.001]

[Cites] J Clin Oncol. 2008 Oct 20;26(30):4952-7 [18606983.001]

[Cites] Blood. 2009 Apr 30;113(18):4144-52 [19168784.001]

[Cites] J Clin Oncol. 2002 Aug 1;20(15):3262-9 [12149300.001]

(PMID = 20210368.001).

[ISSN] 1179-1969

[Journal-full-title] Drugs & aging

[ISO-abbreviation] Drugs Aging

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] New Zealand

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] CNS prophylaxis in lymphoma: who to target and what therapy to use.

The purpose of this article is to review the current data on the risk of CNS relapse in patients with lymphoma and the efficacy of CNS directed prophylactic therapy.

CNS relapse occurred in 30-50% of those with Burkitt lymphoma and acute lymphoblastic leukaemia/lymphoma prior to the introduction of intensified regimens that include CNS prophylaxis.

Most patients with AIDS-related-lymphoma receive a short course of intrathecal prophylaxis but a re-evaluation of type and targeting of CNS prophylaxis is needed.

Patients with diffuse large B-cell lymphoma (DLBCL) have a 5% overall risk of CNS relapse but a high risk sub-population can be identified on the basis of raised LDH and >1 extranodal site, testicular or primary breast involvement.

[MeSH-major] Central Nervous System Neoplasms / complications. Central Nervous System Neoplasms / prevention & control. Lymphoma / complications. Lymphoma / prevention & control

MedlinePlus Health Information. consumer health - Lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16884838.001).

[ISSN] 0268-960X

[Journal-full-title] Blood reviews

[ISO-abbreviation] Blood Rev.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Scotland

[Chemical-registry-number] 0 / Antineoplastic Agents

[Number-of-references] 151

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Plasmablastic lymphoma of the oral cavity in an HIV-positive child.

A provisional diagnosis of non-Hodgkin's lymphoma or embryonal rhabdomyosarcoma was made.

Fine-needle aspiration cytology findings were inconclusive, and incisional biopsy tissue on routine stains gave an impression of small round cell tumor with plasmacytoid features.

The salient immunostaining was negativity with all routine small round cell tumor markers and positivity with CD138 and lambda light chain restriction.

The heterogeneous presentation of plasmablastic lymphoma as a variant of diffuse large B-cell lymphoma and its histogenesis is documented.

Potential pitfalls and differential characterization of AIDS-plasmablastic lymphoma from other closely related tumors are addressed.

The importance of excluding other common pediatric small round cell tumors by immunohistochemistry is highlighted.

[MeSH-major] HIV Seropositivity / complications. Lymphoma, AIDS-Related / etiology. Lymphoma, Large B-Cell, Diffuse / etiology. Maxillary Neoplasms / etiology

Genetic Alliance. consumer health - HIV.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16301154.001).

[ISSN] 1528-395X

[Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics

[ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Immunoglobulin lambda-Chains; 0 / Membrane Glycoproteins; 0 / Proteoglycans; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / Syndecans

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Successfully cured primary esophageal lymphoma in a patient with acquired immune deficiency syndrome (AIDS).

[MeSH-major] Esophageal Neoplasms / drug therapy. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - Esophageal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19544273.001).

[ISSN] 1438-8812

[Journal-full-title] Endoscopy

[ISO-abbreviation] Endoscopy

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Germany

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The association between non-Hodgkin lymphoma and renal cell carcinoma in an HIV-positive patient: clinico-pathological features and pathogenic implications.

[MeSH-major] Carcinoma, Renal Cell / etiology. Epstein-Barr Virus Infections / complications. HIV Infections / complications. Kidney Neoplasms / etiology. Lymphoma, AIDS-Related / etiology. Lymphoma, Large B-Cell, Diffuse / etiology. Neoplasms, Multiple Primary / etiology

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

Genetic Alliance. consumer health - HIV.

Genetic Alliance. consumer health - Renal cell carcinoma.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - Kidney Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18615452.001).

[ISSN] 1096-8652

[Journal-full-title] American journal of hematology

[ISO-abbreviation] Am. J. Hematol.

[Language] eng

[Publication-type] Case Reports; Letter

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Recreational amphetamine use and risk of HIV-related non-Hodgkin lymphoma.

The results of many laboratory studies suggest that amphetamine use may lead to altered immune function and cytokine expression, both of which are implicated in HIV-related lymphomagenesis.

We examined the hypothesis that use of amphetamines modifies risk of non-Hodgkin lymphoma (NHL) in HIV-infected men in the Multicenter AIDS Cohort Study.

Similar associations were observed when we separately examined systemic NHL and diffuse large B-cell lymphoma.

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. AMPHETAMINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Eur J Epidemiol. 2004;19(6):585-7 [15330132.001]

[Cites] Immunology. 2004 Apr;111(4):357-67 [15056370.001]

[Cites] Am J Epidemiol. 1987 Aug;126(2):310-8 [3300281.001]

[Cites] J Acquir Immune Defic Syndr. 1989;2(1):77-83 [2918462.001]

[Cites] Life Sci. 1991;49(16):PL107-12 [1910138.001]

[Cites] Immunopharmacol Immunotoxicol. 1994 Feb;16(1):1-21 [8169319.001]

[Cites] Life Sci. 1996;58(2):PL 29-33 [8606616.001]

[Cites] Am J Epidemiol. 1996 Feb 15;143(4):374-9 [8633621.001]

[Cites] Epidemiology. 1996 Mar;7(2):131-9 [8834551.001]

[Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Jul 1;15(3):211-22 [9257656.001]

[Cites] Br J Cancer. 1997;76(11):1532-7 [9400954.001]

[Cites] Immunopharmacology. 1998 Jan;38(3):253-60 [9506825.001]

[Cites] J Neuroimmunol. 1998 Mar 15;83(1-2):133-8 [9610681.001]

[Cites] J Neuroimmunol. 1998 Mar 15;83(1-2):139-47 [9610682.001]

[Cites] Mem Inst Oswaldo Cruz. 1998 May-Jun;93(3):373-81 [9698872.001]

[Cites] AIDS Educ Prev. 1999 Jun;11(3):232-42 [10407457.001]

[Cites] AIDS Read. 2004 Nov;14(11):605-17 [15570672.001]

[Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]

[Cites] Scand J Infect Dis. 2005;37(6-7):493-6 [16012010.001]

[Cites] Int J Obes (Lond). 2005 Oct;29(10):1267-74 [15997248.001]

[Cites] AIDS. 2005 Oct 14;19(15):1711-2 [16184051.001]

[Cites] Tumour Biol. 2006;27(4):187-94 [16651853.001]

[Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]

[Cites] PLoS Med. 2006 Nov;3(11):e438 [17121449.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):392-5 [17337642.001]

[Cites] Int J Cancer. 2007 Oct 1;121(7):1564-70 [17443495.001]

[Cites] Subst Use Misuse. 2007;42(10):1613-28 [17918031.001]

[Cites] AIDS Care. 2007 Oct;19(9):1134-40 [18058397.001]

[Cites] AIDS. 2008 Jan 30;22(3):357-65 [18195562.001]

[Cites] Lancet. 2008 Feb 16;371(9612):569-78 [18280327.001]

[Cites] J Immunol. 2000 Jun 15;164(12):6461-6 [10843702.001]

[Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]

[Cites] Lancet. 2000 Jul 22;356(9226):291-6 [11071184.001]

[Cites] J Pharmacol Exp Ther. 2001 Jan;296(1):207-15 [11123382.001]

[Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]

[Cites] Life Sci. 2001 Nov 2;69(24):2931-41 [11720096.001]

[Cites] Ann N Y Acad Sci. 2002 Jun;965:421-33 [12105117.001]

[Cites] Curr Opin Oncol. 2002 Sep;14(5):528-32 [12192272.001]

[Cites] J Infect Dis. 2003 Feb 15;187(4):700-4 [12599091.001]

[Cites] J Leukoc Biol. 2003 Oct;74(4):486-96 [12960289.001]

[Cites] Clin Immunol. 2003 Nov;109(2):119-29 [14597210.001]

[Cites] J Pharmacol Exp Ther. 2004 Apr;309(1):285-92 [14722327.001]

[Cites] AIDS Care. 2004 Nov;16(8):1036-47 [15511735.001]

(PMID = 19011979.001).

[ISSN] 1573-7225

[Journal-full-title] Cancer causes & control : CCC

[ISO-abbreviation] Cancer Causes Control

[Language] ENG

[Grant] United States / NIAID NIH HHS / AI / U01 AI035042; United States / NIDA NIH HHS / DA / R01 DA008254-12; United States / NIAID NIH HHS / AI / U01 AI037984; United States / NCI NIH HHS / CA / P50 CA096888-05; United States / NIDA NIH HHS / DA / R01 DA08254; United States / NIDA NIH HHS / DA / DA003018-18; United States / NIDA NIH HHS / DA / DA008254-12; United States / NIDA NIH HHS / DA / R37 DA003018; United States / NIDA NIH HHS / DA / R37 DA03018; United States / NIDA NIH HHS / DA / R37 DA003018-21; United States / NIAID NIH HHS / AI / U01 AI037613; United States / NCI NIH HHS / CA / P50 CA096888-01; United States / NCRR NIH HHS / RR / M01 RR000722; United States / NIAID NIH HHS / AI / U01 AI035041; United States / NCI NIH HHS / CA / P50CA096888; United States / NIAID NIH HHS / AI / UM1 AI035043; United States / NIDA NIH HHS / DA / R37 DA003018-18; United States / NIDA NIH HHS / DA / DA008254-06; United States / NIAID NIH HHS / AI / U01 AI035043; United States / NIDA NIH HHS / DA / DA003018-21; United States / NIAID NIH HHS / AI / U01 AI035040; United States / NIDA NIH HHS / DA / R01 DA008254; United States / NCI NIH HHS / CA / CA096888-01; United States / NIDA NIH HHS / DA / R01 DA008254-06; United States / NIAID NIH HHS / AI / U01 AI035039; United States / NCI NIH HHS / CA / P50 CA096888

[Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Street Drugs; CK833KGX7E / Amphetamine

[Other-IDs] NLM/ NIHMS192303; NLM/ PMC2862618

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Therapy-related acute myeloid leukemia following HIV-associated lymphoma.

In the highly active antiretroviral therapy era, an increasingly large number of HIV-infected patients are developing non- AIDS-defining cancers (NADCs).

As patients survive longer, long-term therapy-related complications take on greater importance.

Herein, we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma.

With the diagnosis of therapy-related acute myeloid leukemia (AML) secured, he began induction chemotherapy with idarubicin and cytarabine.

Through a literature search, we were able to identify 4 additional cases of therapy-related AML in AIDS patients following chemotherapy for lymphomas.

The median age of these patients at the time of AML diagnosis was 39 years (range, 33-59 years), the median time from the treatment of lymphoma to AML was 18 months (range, 11-48 months), and the median survival following induction chemotherapy was 4 weeks (range, 2-16 weeks).

With many HIV-infected patients surviving alkylator and topoisomerase inhibitor-based treatment and radiation therapy for AIDS-defining cancers and NADCs, long-term follow-up for therapy-related complications assumes greater importance.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / chemically induced. Lymphoma, AIDS-Related / drug therapy

Genetic Alliance. consumer health - Leukemia, Myeloid.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19717383.001).

[ISSN] 1938-0712

[Journal-full-title] Clinical lymphoma & myeloma

[ISO-abbreviation] Clin Lymphoma Myeloma

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS and non-AIDS diffuse large B-cell lymphomas express different antigen profiles.

Based on gene expression profiling, diffuse large B-cell lymphomas arising in immunocompetent patients can be divided into germinal center and activated B-cell types.

Since little is known about acquired immunodeficiency syndrome associated diffuse large B-cell lymphomas, we tested whether the protein expression of germinal center and activated B-cell markers differed between acquired immunodeficiency syndrome (AIDS) vs non-AIDS diffuse large B-cell lymphomas.

We immunohistochemically stained tissue microarrays of 39 de novo diffuse large B-cell lymphomas: 12 AIDS associated and 27 non-AIDS, with germinal center (BCL6, CD10, CyclinH) and activated B-cell markers (MUM1, CD138, PAK1, CD44, BCL2).

The activated B-cell and germinal center summation scores of each case were used as (x, y) coordinate data points to construct two-dimensional contour-frequency plots.

The contour plot of non-AIDS diffuse large B-cell lymphomas showed two distinct clusters: a cluster with a high germinal center phenotype (cluster 1) and a cluster with a high activated B-cell phenotype (cluster 3).

In contrast, the AIDS-related diffuse large B-cell lymphomas formed a single aggregate (cluster 2) (P=0.02, Fisher exact test).

When the contour plots of the AIDS-related and the non-AIDS cases were superimposed, cluster 2 of the AIDS cases expressed an intermediate germinal center/activated B-cell phenotype compared to clusters 1 and 3 of the non-AIDS diffuse large B-cell lymphomas.

Our results confirm that non-AIDS diffuse large B-cell lymphomas segregate into two groups with either germinal center or activated B-cell phenotype.

We report the new finding that the AIDS status of the patient predicts the immunophenotype of the diffuse large B-cell lymphomas.

[MeSH-major] Lymphoma, AIDS-Related / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - B-Cell Lymphomas.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16444194.001).

[ISSN] 0893-3952

[Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

[ISO-abbreviation] Mod. Pathol.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Interferon Regulatory Factors; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-myc; 0 / interferon regulatory factor-4; EC 3.4.24.11 / Neprilysin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Humans. Hyperuricemia / drug therapy. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Male. Mycosis Fungoides / drug therapy. Product Surveillance, Postmarketing. Sarcoidosis, Pulmonary / drug therapy. Treatment Outcome. Tumor Lysis Syndrome / drug therapy. Uric Acid / metabolism

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 1183685241 for PMID:17169811 [PharmGKB] .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17169811.001).

[ISSN] 1042-8194

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Publication-type] Case Reports; Letter

[Publication-country] England

[Chemical-registry-number] 268B43MJ25 / Uric Acid; EC 1.7.3.3 / Urate Oxidase; EC 1.7.3.3. / rasburicase

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Autologous stem-cell transplantation in patients with HIV-related lymphoma.

PURPOSE: Peripheral-blood autologous stem-cell transplantation (ASCT) in patients with HIV-related lymphoma (HIV-Ly) has been reported as a safe and useful procedure.

RESULTS: Since 1999, 68 patients from 20 institutions (median age, 41 years; range, 29 to 62 years) were included, diagnosed with non-Hodgkin's lymphoma (NHL; n = 50) or Hodgkin's lymphoma (n = 18).

CI of relapse was 30.4% at 24 months, statistically related with not being in CR at ASCT (relative risk [RR] = 3.6), NHL histology other than diffuse large B-cell lymphoma (RR = 3.4), and use of more than two previous treatment lines (RR = 3).

CONCLUSION: Similarly to HIV-negative patients with lymphoma, ASCT is a useful treatment for patients with HIV-Ly and is associated with low NRM, mainly when performed in early stages and chemo-S disease.

[MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, AIDS-Related / therapy

Genetic Alliance. consumer health - Transplantation.

Genetic Alliance. consumer health - HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[ErratumIn] J Clin Oncol. 2009 Jul 1;27(19):3263

(PMID = 19332732.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

[Publication-country] United States